Emmanuel Hanon | Chair, Scientific Advisory Board
Astrivax

Dr Emmanuel Hanon is a vaccine executive with over 20 years of global leadership in vaccine research and development, bringing a foundational background in veterinary medicine, virology, and immunology. He previously served as Senior Vice President and Head of Global Vaccines R&D at GSK, where he directed discovery and life-cycle development across a major portfolio that included vaccines for shingles (Shingrix), quadrivalent influenza, malaria (Mosquirix), RSV, and pandemic influenza adjuvants. He subsequently served as Chief Executive Officer of Vicebio, leading the clinical development of 'Molecular Clamp' technology for next-generation respiratory combination vaccines through its acquisition by Sanofi. Dr Hanon has also played a key role in global pandemic preparedness as Chair of the Scientific Advisory Committee for the Coalition for Epidemic Preparedness Innovations (CEPI). He is currently Chair of the AstriVax Scientific Advisory Committee.

Appearances:

Day 2 (21st October) @ 12:45

Panel: From Bottleneck to Breakthrough: Reengineering Vaccine Clinical Development

The COVID-19 pandemic demonstrated that vaccine development can be dramatically accelerated, raising industry expectations for faster development timelines. Several years later, timelines have largely reverted to pre-COVID norms. At the same time, the vaccine landscape has become increasingly crowded and competitive.

In this environment, trial productivity has become a strategic differentiator. This panel will take stock of today’s vaccine development landscape and explore what developers can do differently to accelerate development. The discussion will focus on the levers with the greatest potential to improve speed and productivity, including the opportunities emerging in the age of AI, and bring together perspectives from biotech, large vaccine companies, and the public sector.

Session led by: